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ABSTRACT
Introduction Major depressive disorder (MDD) and 
obesity are both common disorders associated with 
significant burden of disease worldwide. Importantly, MDD 
and obesity often co- occur, with each disorder increasing 
the risk for developing the other by about 50%–60%. 
Statins are among the most prescribed medications 
with well- established safety and efficacy. Statins are 
recommended in primary prevention of cardiovascular 
disease, which has been linked to both MDD and obesity. 
Moreover, statins are promising candidates to treat MDD 
because a meta- analysis of pilot randomised controlled 
trials has found antidepressive effects of statins as adjunct 
therapy to antidepressants. However, no study so far has 
tested the antidepressive potential of statins in patients 
with MDD and comorbid obesity. Importantly, this is a 
difficult- to- treat population that often exhibits a chronic 
course of MDD and is more likely to be treatment resistant. 
Thus, in this confirmatory randomised controlled trial, we 
will determine whether add- on simvastatin to standard 
antidepressant medication with escitalopram is more 
efficacious than add- on placebo over 12 weeks in 160 
patients with MDD and comorbid obesity.
Methods and analysis This is a protocol for a 
randomised, placebo- controlled, double- blind multicentre 
trial with parallel- group design (phase II). One hundred 
and sixty patients with MDD and comorbid obesity will be 
randomised 1:1 to simvastatin or placebo as add- on to 
standard antidepressant medication with escitalopram. 
The primary outcome is change in the Montgomery-Åsberg 
Depression Rating Scale (MADRS) score from baseline to 
week 12. Secondary outcomes include MADRS response 
(defined as 50% MADRS score reduction from baseline), 
MADRS remission (defined as MADRS score <10), mean 
change in patients’ self- reported Beck Depression 
Inventory (BDI- II) and mean change in high- density 
lipoprotein, low- density lipoprotein and total cholesterol 
from baseline to week 12.
Ethics and dissemination This protocol has been 
approved by the ethics committee of the federal state of 
Berlin (Ethik- Kommission des Landes Berlin, reference: 
19/0226—EK 11) and by the relevant federal authority 
(Bundesinstitut für Arzneimittel und Medizinprodukte 
(BfArM), reference: 4043387). Study findings will be 
published in peer- reviewed journals and will be presented 
at (inter)national conferences.
Trial registration numbers NCT04301271, 
DRKS00021119, EudraCT 2018-002947-27.
INTRODUCTION
Scientific background and study rationale
The WHO’s global burden of disease (GBD) 
study demonstrated that of all diseases 
worldwide, major depressive disorder 
(MDD) is among the top five with regard 
to years lived with disability1 and by far the 
leading cause of disability resulting from 
all psychiatric disorders.2 The 12 months 
Strengths and limitations of this study
 ► This is a confirmative randomised controlled trial to 
examine the antidepressive potential of simvastatin 
as add- on therapy in patients with major depressive 
disorder (MDD) and comorbid obesity.
 ► Importantly, depressed patients with obesity are a 
difficult- to- treat population that often exhibits a 
chronic course of MDD and treatment resistance.
 ► This trial is not designed to examine long- term ef-
fects of add- on statin therapy (beyond 12 weeks of 
follow- up).
 ► This trial is not powered to explore effects in sub-
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prevalence of MDD in adults according to the World 
Mental Health Survey is approximately 6%, which is 
comparable to estimates from other (inter- )national 
surveys.3 Mortality rates in MDD are twice as high as in 
the general population and translate to a reduced life 
expectancy of approximately 14.0 years in men and 10.1 
years in women based on a cohort study of all Danish 
residents aged 15 or older.4
According to the GBD study, the overall prevalence of 
obesity in adults was 12.0% in 2015 and ranged from 1.6% 
in Vietnam to 34.9% in Egypt.5 According to the latest 
global estimates of the WHO, 11% of adult men and 15% 
of adult women were obese in 2016 and the prevalence 
ranged from 29% among the Region of the Americas to 
2% in some of the West African countries.6 In the German 
adult population (age range: 18–79 years), the prevalence 
of obesity is 23.3% in men and 23.9% in women, respec-
tively.7 In adult patients with obesity, mortality rates are 
elevated (HR 1.64, CI 1.61 to 1.67) and they increase in 
relation to body mass index (BMI) as recently confirmed 
in a meta- analysis of 239 studies from four continents.8 In 
the GBD study, obesity was estimated to cause 3.4 million 
deaths in the general population, and accounted for 
3.9% of years of life lost, and 3.8% of disability- adjusted 
life years worldwide.9
MDD and obesity are both linked to a higher risk of 
cardiovascular disease and stroke, further increasing their 
public health and economic impact. Importantly, MDD 
and obesity frequently co- occur and the presence of one 
condition increases the risk for developing the other by 
approx. 50%–60%.10
Statins (3- hydroxy-3- methylglutaryl coenzyme A 
reductase inhibitors) are among the most prescribed 
medications worldwide with well- established safety 
and efficacy. Recent guidelines recommend the use of 
statins in primary prevention of cardiovascular disease,11 
which has been linked to both MDD and obesity. More-
over, statins are promising candidates to treat MDD. 
Evidence for antidepressive effects of statins has accumu-
lated from four independent lines of research: animal 
studies,12 meta- analysis of prospective cohort studies,13 
meta- analysis of pilot controlled trials14 and a nationwide 
cohort study.15 However, no randomised controlled study 
so far has tested the antidepressive potential of statins 
in patients with MDD and comorbid obesity. Impor-
tantly, this is a difficult- to- treat population that often 
exhibits a chronic course of MDD and is more likely to 
show treatment resistance to standard pharmacological 
therapy.16 17 Depressed patients who are overweight or 
obese responded significantly slower to antidepressant 
treatment compared with normal- weight patients.18 In a 
recent scoping review, excess body weight predicted non- 
response to treatment with antidepressants.19 Given the 
enormous public health impact of MDD and obesity and 
given the evidence of antidepressive effects of statins, a 
controlled trial of adjunct statin treatment in comorbid 
patients appears warranted.
STUDY AIMS AND HYPOTHESIS
Primary
To examine whether add- on 40 mg/d simvastatin to stan-
dard antidepressant medication (escitalopram 20 mg/d) 
(SIM+ES) improves depression to a greater extent than 
adjunct placebo (PL+ES) in patients with MDD and 
comorbid obesity over a period of 12 weeks. We hypothe-
sise that SIM+ES will improve depression to a greater extent 
than PL+ES in patients with comorbid obesity and major 
depression.
Secondary
To examine whether SIM+ES improves response rates, 
remission rates, self- reported depression, patients’ 
impression of change, clinicians’ impression of severity 
and change, quality of life, social functioning, lipid 
values and immune function and cellular metabolism 
to a greater extent than PL+ES in patients with major 
depression and comorbid obesity. We hypothesise that 
SIM+ES will improve (a) response rates and remission 
rates, (b) patients’ impression of change, clinicians’ 
impression of severity and improvement, quality of life, 
social functioning, self- report depression, (c) lipid values 
and (d) immune function and cellular metabolism to a 
greater extent over 12 weeks than PL+ES in patients with 
comorbid obesity and major depression.
METHODS
This protocol has been prepared in accordance with the 
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) 2013 statement.20 Please see online 
supplemental table 1 for the SPIRIT checklist.
Study design and sample
The study will include 160 patients divided into two treatment 
groups and recruited from several centres (public academic 
hospitals/departments) located in Germany. Group 1 will 
receive placebo add- on to escitalopram (PL+ES) and group 
2 will receive simvastatin add- on to escitalopram (SIM+ES). 
For an overview of the study design, please see figure 1.
Patients will be recruited from depression and obesity 
outpatient clinics and inpatient wards from each study 
site. In addition, we will use existing and established 
networks of all sites within the psychiatric community to 
include depressed out- patients from general practitioners 
and psychiatrists. Thus, we will ensure high generalis-
ability of our study population. There will be no specific 
sex distribution as no sex specific differences concerning 
efficacy and safety of simvastatin are expected. The first 
study sites have been initiated in March 2020 and the 
study is expected to end in January 2023.
Eligibility criteria and assessment
The main inclusion criteria for the SIMCODE trial are as 
follows: (i) written informed consent; (ii) major depres-
sive episode according to DSM 5 (Diagnostic and Statis-
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Montgomery-Åsberg Depression Rating Scale (MADRS) 
score ≥18; (iv) BMI ≥30; (v) age between 18 and 65 years 
(≥18 und≤65); (vi) in case of non- psychotropic medication: 
stable pharmacological medication for at least 14 days prior 
to study entry; (vii) no antidepressant intake during the last 
7 days prior to study entry (discontinuation of effective medi-
cation to enable study participation is prohibited); (viii) no 
prior treatment with escitalopram in index episode; (ix) 
less than three trials with antidepressants in index episode; 
(x) no treatment with ketamine, electroconvulsive therapy 
(ECT) or other stimulatory treatments in index episode; (xi) 
none of the following disorders: schizophrenia, schizoaffec-
tive disorder and bipolar disorder. In addition, patients with 
any severe, unstable general medical condition or contrain-
dications for simvastatin or escitalopram will not be included 
in the study.
Main exclusion criteria are as follows: (i) current use of 
statins; (ii) current use of antidepressants; (iii) acute suicidal 
tendencies (MADRS Item 10>4); (iv) pregnancy, breast-
feeding or women with childbearing potential without 
acceptable form of contraception (defined as Pearl index 
<1); (v) current use of psychotropic medication (eg, antipsy-
chotics, anticonvulsants, lithium or St. John’s Wort) except 
for benzodiazepines, non- benzodiazepines and opiates 
(vi) clinically significant abnormalities in 12- lead ECG (eg, 
corrected Q–T interval prolongation ≥500 ms or increase 
≥60 ms from baseline visit). In addition, there are several 
more exclusion criteria including medication that is contra-
indicated with simvastatin or escitalopram. Please see online 
supplemental table 2 for complete inclusion and exclusion 
criteria.
A screening visit will be carried out to establish eligibility 
and to obtain informed consent. After informed consent, we 
will assess the severity of depressive episode using MADRS, 
duration of the index episode, number of episodes, previous 
treatment as requested by the guideline of the Euro-
pean Medicines Agency on clinical trials in depression.21 
During the screening visit, several other procedures will be 
performed including a physical examination, Mini Interna-
tional Neuropsychiatric Interview (MINI; German Transla-
tion V.7.0.2),22 measurement of body weight and height for 
determination of BMI, ECG and safety laboratory including 
pregnancy test for women.
To ensure that the study is conducted according to the 
study protocol, to current laws and to general guidelines, 
a training of all investigators/subinvestigators have been 
conducted prior to initiation. The trial will be initiated by 
the principal investigator (PI) team (CO, WRC) and a trial 
monitor at each site before patient enrolment at that site 
begins.
Figure 1 Study flow chart according to CONSORT. We assume that we need to screen n=1125 patients aged 18–65 with 
major depression according to Diagnostic and Statistical Manual of Mental Disorders five and obesity (body mass index ≥30) 
for eligibility at eight recruiting centres to randomise n=160 participants. The sample size and assumed dropout rate (20%) 
is conservatively based on three earlier pilot RCTs of add- on statin to SSRI treatment in depressed patients. CONSORT, 
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Intervention
Each patient in this study will be treated with escitalo-
pram, a well- established standard- antidepressant, which 
is readily available because it is commonly used as generic 
drug in Germany. Add- on placebo serves as the control 
condition for adjunct simvastatin (40 mg/d). Simvas-
tatin and placebo will be provided by the pharmacy of 
the Charité—Universitätsmedizin Berlin and will be 
administered in a double- blind fashion. Escitalopram 
will be provided by the pharmacy of the Charité, stored 
and dispensed at each study site in a non- blinded fashion. 
Patients will receive simvastatin or placebo orally in a 
fixed dosage of 40 mg once a day at bedtime. Patients will 
receive 10 mg escitalopram orally in a fixed dosage of 10 
mg once a day in the morning for the first 2 weeks, then 
increased to 20 mg once a day in the morning until the 
end of study. Drug dispensation will take place at baseline 
(visit 1), at visit 3 (only escitalopram), visit 4 and visit 5. 
See figure 2 for scheme of intervention.
Rationale for statin choice and dosage
Among the available stains, we decided to use simvas-
tatin (SimvaHEXAL) in a dosage of 40 mg/d based on 
the following considerations: simvastatin was used in this 
dose in one of three randomised controlled trials (RCTs) 
showing evidence versus placebo as adjunct treatment to 
selective serotonin reuptake inhibitors (SSRIs);23 it was 
superior to atorvastatin in depressed patients with heart 
disease;24 it passes the blood–brain barrier25 and it is 
available as generic drug (costs for 40 mg/d simvastatin: 
around 100 EUR per year). We decided against using a 
dose of 80 mg/d simvastatin due to the increased risk of 
muscle injury and the corresponding warning from the 
US Food and Drug Administration26 (see 3.8 Safety).
Rationale for antidepressant choice and dosage
All depressed patients enrolled in the trial will be contin-
uously treated with a gold standard antidepressant 
(escitalopram) as described by the German National 
Disease Management Guideline (‘Nationale Versorgung-
sleitlinie’) for the treatment of MDD. For escitalopram, 
a dose–response relationship has been suggested. Espe-
cially for patients with severe depression, the high stan-
dard dose of 20 mg/d was shown to be superior compared 
with 10 mg/d.27 A fixed- dose of 10 mg/d escitalopram 
for the entire study duration of 12 weeks would therefore 
not allow the optimal treatment for some patients. Thus, 
we consider this option ethically not justifiable. A dose 
increase from 10 to 20 mg/d based on individual patient 
response would however interfere with comparability of 
the SIM+ES group and PL+ES group, because a strong 
decrease in depressive symptoms in the SIM+ES group 
compared with PL+ES group could potentially be masked 
by a higher percentage of escitalopram dose escalation 
in the PL+ES group. Therefore, we will increase escitalo-
pram to 20 mg/d after giving a low standard dose of 10 
mg/d in the first 2 weeks. In case of adverse reactions 
Group 1: Placebo + Escitalopram (n=80) 
Group 2: Simvastatin 40 mg/day + Escitalopram (n=80)
Baseline
Visit 1












Exclusion criteria Exclusion criteria Exclusion criteria Exclusion criteria




Clinical scores Clinical scores Clinical scores Clinical scores
Blood pressure/heart rate Blood pressure/heart rate
ECG






























































Figure 2 Scheme of intervention in SIMCODE study. Overview of design and procedures of the SIMCODE study. BDI- II, Beck- 
Depressions- Inventar II; BMI, body mass index; CGI- I, Clinicians’ Global Impression of Improvement; CGI-S, Clinicians’ Global 
Impression of Severity of illness; EQ- 5D-3L, Generic Quality of Life Questionnaire; MADRS, Montgomery-Åsberg Depression 
Scale; MINI, Mini International Neuropsychiatric Interview; PGIC, Patient Global Impression of Change; SOFAS, Social and 
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related to escitalopram, we will follow the instructions for 
dose adjustment described in 3.8 Safety.
Patients are instructed to return unused medication 
and compliance will be determined by count of the 
remaining pills and patients will be considered compliant 
if they report taking more than 90% of their drug (as 
in previous studies with simvastatin in central nervous 
system diseases).28 29
Permitted comedications
Medication that is contraindicated with simvastatin, and 
escitalopram or concomitant treatment with antidepres-
sants other than escitalopram will not be permitted (see 
inclusion/exclusion criteria in online supplemental table 
S2). In case of current treatment with antidepressants at 
study entry, a wash- out of prior antidepressants for at least 
seven drug- free days prior to inclusion may be permitted 
(see inclusion criteria in online supplemental table S2). 
However, discontinuation of effective medication to 
enable study participation is prohibited. Other psycho-
tropic drugs (including antipsychotics, anticonvulsants, 
lithium or St. John’s Wort) are not permitted during the 
study period with the following exceptions: (1) in case 
of sleep difficulties, benzodiazepine or nonbenzodiaze-
pine hypnotics (eg, zolpidem, zopiclone) will be allowed 
on an ‘as needed basis’; (2) in case of acute anxiety or 
agitation, a benzodiazepine (preferably lorazepam) may 
be prescribed not exceeding 3 mg/d (other benzodiaze-
pines at the equivalent dosage), (3) opiates for pain relief 
(see exclusion criteria in online supplemental table S2). 
Any clinical exacerbation requiring a higher benzodiaz-
epine regimen or prescription of antipsychotics (‘rescue 
medication’) will be considered as a serious adverse event 
(SAE) (see 3.8 Safety and online supplemental material). 
In case of non- psychotropic medication, stable pharmaco-
logical medication for at least 14 days prior to study entry 
will be permitted. Patients with any changes in medication 
dose or frequency of therapy during the 14 days prior to 
study entry will not participate in the study (see inclusion 
criteria in online supplemental table S2). Concomitant 
use of statins will not be permitted (see exclusion criteria 
in online supplemental table S2).
Sample size calculation
So far, there are three small pilot RCTs in depressed 
patients (sample sizes ranging from n=48 to n=68) that 
have all found statistically significant beneficial effects of 
add- on statins versus placebo with large, clinically rele-
vant effect sizes. A meta- analysis14 of these trials has found 
a standardised mean difference between add- on statins 
and add- on placebo of −0.73 (95 % CI −1.04 to −0.42, 
p<0.001). However, it is well known that initial studies 
tend to overestimate the true effect size.30 Therefore, we 
conservatively assume a standardised treatment differ-
ence (also known as Cohen’s d) of 0.5, which is smaller 
than those reported by the three pilot RCTs.23 31 32 Given 
a SD of 6–8 points on the MADRS, as commonly observed 
in RCTs in this population,33–35 a standardised effect size 
of 0.5 translates into a mean difference of 3–4 points, 
which is considered clinically relevant because it is about 
twice as large as the minimal clinically important differ-
ence (MCID) of 1.6–1.9 points that has been reported 
for the MADRS.36 Thus, a sample size of 64 patients per 
group results in a power of 80% for a comparison of the 
mean changes in MADRS score from baseline to week 
12 between the two groups using a two- sample t- test at 
the usual two- sided level of 5%. As the analyses will be 
adjusted for baseline scores, the actual power is likely to 
be higher; this will be confirmed in a blinded sample size 
review once 50% of the patients have reached week 12.37 
Accounting for about 20% dropout, we aim to recruit 
80 patients per group (ie, 160 patients in total). Based 
on sex- specific prevalence rates and recruitment in our 
earlier studies,38 39 we expect that about two- thirds of the 
sample will be women. This will allow sex- specific analyses.
As the analyses will be adjusted for baseline scores, the 
actual power is likely to be higher than 80%. To confirm 
this in an interim analysis, a blinded sample size review 
will be carried out, once 50% of the patients have reached 
week 12. Based on blinded estimates of the mean square 
error and the dropout rate, the required sample size will 
be recalculated and the sample size will be adjusted up to a 
maximum total sample size of 240 patients, if necessary.37
Outcomes
As primary outcome variable, we will use the change in 
MADRS40 score from baseline to week 12. As secondary 
outcome variables, we will use MADRS response (defined 
as 50% MADRS score reduction from baseline), MADRS 
remission (defined as MADRS score <10) and MADRS 
MCID. Also, we will assess as secondary outcome variables 
change scores in patients’ self- reported Beck Depression 
Inventory (BDI- II) as well as the MCID according to BDI.41 
We will additionally determine the clinician’s impres-
sion of the severity of illness (Clinical Global Impression 
scale—Severity of illness),42 the clinician’s impression 
whether and to what extent symptoms have improved 
(Clinical Global Impression scale—Improvement),42 the 
patient’s impression whether and to what extent symp-
toms have improved (Patients’ Global Impression of 
Change Scale), social functioning (Social and Occupa-
tional Functioning Assessment Scale, SOFAS), quality of 
life (EuroQol-5 Dimensions-3 Levels Questionnaire), with 
a calculated MCID43 and change scores in high- density 
lipoprotein, low- density lipoprotein and total cholesterol. 
At selected sites, additional blood samples for assessment 
of immune function and cellular metabolism will be 
obtained and analysed in an exploratory fashion. For the 
characteristics and definitions of primary and secondary 
endpoints, see table 1. The efficacy and other outcome 
assessments at screening, baseline and different follow- up 
visits are shown in table 2.
Randomisation and blinding
Subjects will be randomised 1:1 to simvastatin or placebo 
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Table 1 Characteristics and definitions of primary and secondary endpoints
Outcome Instrument Rating Domain Exactly defined outcome Variable
Primary MADRS*† Clinician- rated Severity of depression Mean change from baseline Continuous
Secondary/efficacy 
(exploratory)
MADRS*† Clinician- rated Severity of depression  ► Percentage response 
(>50% reduction from 
baseline)
 ► Percentage remission 
(MADRS score <10 post- 
treatment)
 ► Percentage minimal 
clinically important 
difference (MCID; change 




BDI- II†‡ Self- rated Severity of depression  ► Mean change from 
baseline






CGI- S†§ Clinician- rated Severity of illness Median change from baseline Ordinal
Secondary 
exploratory
CGI- I†¶ Clinician- rated Improvement/worsening 
of illness
Response defined as ‘much 





PGIC†** Self- rated Subjective improvement Response defined as ‘much 





SOFAS††† Clinician- rated Social functioning Mean change from baseline Continuous
Secondary 
exploratory
EQ- 5D- 3L†‡‡ Self- rated Quality of life Mean change from baseline
percentage MCID (change 

















Immune function Mean change from baseline Continuous
*The MADRS is a rating scale to measure depression severity. Each MADRS item is rated on a 0–6 scale. Total score ranges from 0 to 60, 
where higher MADRS scores indicate higher levels of depressive symptoms.
†This instrument has been validated in German.
‡The Beck Depression Inventory- II is a 21- item validated instrument for the self- report of depressive symptoms, with individual item 
scores summed to yield a total possible BDI score that ranges from 0 to 63. BDI scores from 0 to 13 suggest absent to minimal depressive 
symptoms, from 14 to 19 mild symptoms, from 20 to 28 moderate symptoms and from 29 to 63 severe symptoms.
§The CGI- S evaluates the severity of psychopathology on a scale of 0–7. Considering total clinical experience, a participant is assessed 
on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 
4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.
¶The CGI- I is a clinician- rated instrument to measure clinicians’ change in overall status on a scale ranging from 1 (very much improved) to 7 
(very much worse).
**The PGIC is a participant- rated instrument to measure participant’s change in overall status on a scale ranging from 1 (very much improved) 
to 7 (very much worse).
††The SOFAS is a rating scale used to determine social functioning on a scale ranging from 0 to 100. A higher score represents better social 
and occupational functioning.
‡‡The EQ- 5D- 3L is a generic instrument of quality of life related to health. It contains five dimensions of health (mobility, personal care, daily 
activities, pain/discomfort and anxiety/depression) and each of them has three levels of seriousness (without problems, some problems or 
moderate problems and serious problems). The second part of the EQ- 5D is a Visual Analogue Scale ranging from 0 (worse health status 
imaginable) to 100 (best imaginable health status). In it, the individual must mark the point in the vertical line that best reflects the assessment 
of their global health status today.
BDI- II, Beck- Depressions- Inventar II; BMI, body mass index; CGI- I, Clinicians’ Global Impression of Improvement; CGI- S, Clinicians’ Global 
Impression of Severity of illness; EQ- 5D- 3L, Generic Quality of Life Questionnaire; MADRS, Montgomery-Åsberg Depression Scale; MINI, 
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by the trial statistician. The randomisation will be based 
on a permuted block procedure stratified by study site.
Based on the randomisation codes, the pharmacy 
will centrally provide for each centre sequentially 
numbered, tamper- proof container, which are equal in 
weight and similar in appearance containing simvas-
tatin or placebo. The pharmacy keeps the randomis-
ation list unavailable to investigators/subinvestigators 
and the sponsor/sponsor representative until the end 
of study. Investigators/subinvestigators and patients 
will be blinded to the treatment. Simvastatin is an 
effective serum lipid- lowering drug that can decrease 
lipid levels. Particularly, LDL cholesterol is expected 
to be lower in the SIM+ES group. In order to ensure 
continued blinding, lipid values will be assessed only 
at V1 and the last trial visit (V6) to minimise the 
risk for unblinding of investigators/subinvestiga-
tors by revealing the lipid profile. At the same time, 
not assessing the lipid status of patients during the 
entire study participation would not represent current 












End- of- study (visit 6)
week 12
Screening and consent             
  Informed consent X           
  Inclusion criteria X         
  Exclusion criteria X X X X X X
  Medical history X           
  Treatment status X         
  MINI—DSM-5 X           
  Urine/serum drug screening X           
  Concomitant medication X           
Safety             
  Physical exam X         X
  ECG X X X X X X X
  Blood pressure and heart rate X X X X X X X
  Safety laboratory (incl. 
pregnancy test—women only)
X X   X X X
  Adverse events recording   X X X X X
Effectiveness             
  MADRS X X X X X X X
  BDI- II X X X X X X
Social functioning and quality of life             
  SOFAS X   X X
  EQ- 5D- 3L X   X X
Other             
  Demographics X           
  BMI X X       X
  Waist circumference X       X
  PGIC   X X X X X
  CGI- S X X X X X X
  CGI- I   X X X X X
  Laboratory (lipid assessment) X       X
  Laboratory (immune function and 
cellular metabolism)
X   X X X
  Drug dispensation X X X X
BDI- II, Beck- Depressions- Inventar II; BMI, Body- Mass- Index; CGI- I, Clinicians’ Global Impression of Improvement; CGI- S, Clinicians’ 
Global Impression of Severity of illness; EQ- 5D- 3L, Generic Quality of Life Questionnaire; MADRS, Montgomery-Åsberg Depression 



















pen: first published as 10.1136/bm






8 Otte C, et al. BMJ Open 2020;10:e040119. doi:10.1136/bmjopen-2020-040119
Open access 
practice where lipid status is an important part of 
cardiovascular risk assessment. No unblinding of the 
investigators/subinvestigators due to specific side 
effects of simvastatin treatment is to be expected.
In case of an emergency, the blinding will be broken 
immediately, and the patient will receive immediate 
medical care. The local investigator will be responsible 
for deciding if knowledge of the group assignment is 
required for the medical care of the patient and initiate 
the unblinding procedure. Emergency envelopes for the 
unblinding are enclosed in the packages sent to the inves-
tigator site and are stored by the local investigator. When 
emergency envelopes are opened prematurely, date, time, 
reason for opening and name of the person opening have 
to be documented. After unblinding, the treatment of 
the individual participant will be stopped immediately; 
however, the participant will not be excluded from the 
analysis (see online supplemental material for more 
information on premature termination of the individual 
participant). An identical copy of the emergency enve-
lopes for the unblinding will be sent and stored securely 
at the coordinating site (Charité—Universitätsmedizin 
Berlin). This way the coordinating staff is additionally 
available for immediate unblinding.
Safety
Simvastatin and escitalopram are approved for several indi-
cations since decades and have an established safety profile. 
All depressed patients enrolled in the trial will be contin-
uously treated with a gold standard antidepressant (escit-
alopram) as described by the German National Disease 
Management Guideline (‘Nationale Versorgungsleitlinie’) 
for the treatment of MDD. In case of adverse reactions 
related to escitalopram, we will allow dose adjustments such 
as temporary dose reduction from 10 to 5 mg/d or from 20 
to 10 mg/d for the duration of the adverse reaction. See 
table 2 for an overview of safety assessments at screening, 
baseline and different follow- up visits. We list the risks and 
detailed safety considerations for both medications, as 
well as definitions for adverse event (AE), serious AE and 
Suspected Unexpected Serious Adverse Reactions (SUSAR) 
in the online supplemental material.
All (S)AEs and SUSARs will be treated appropriately. 
Such treatment may include changes in study drug treat-
ment including possible interruption or discontinuation, 
starting or stopping concomitant treatments, changes in 
the frequency or nature of assessments, hospitalisation or 
any other medically required intervention. Standard proce-
dures for reporting of (S)AEs and SUSARs will be used.
For specifications for premature termination of the 
individual participant and the clinical study, see online 
supplemental material.
Data management
Patient related data will be recorded in study files (source 
data) under the participant’s real name. The informa-
tion required by the protocol will be entered onto the 
electronic case report forms (eCRF—secuTrial) under a 
pseudonym. Every patient will receive a patient number/
pseudonym which will be unique for this individual 
patient. Data required for the analysis will be acquired 
and transferred electronically to a central database at the 
Coordinating Center for Clinical Studies of Charité by 
means of the electronic data capture system secuTrial). 
The trial data will be stored digitally on a remote server 
with daily backups. After end of study, all data will be 
exported for checks of consistency and plausibility. After 
performing the checks, the data matrix will be transferred 
in pseudonymised form for the statistical evaluation. 
The statistical analysis and the biometrical report will be 
provided by the biostatistician in cooperation with the PI.
Data analysis plan
The primary analysis population will be the intention- to- 
treat (ITT) population. The ITT population will include 
all randomised patients. We will repeat the analyses in the 
per- protocol sample. The primary analysis will compare 
MADRS changes from baseline to week 12 between 
SIM+ES and PL+ES by Gaussian linear models for 
repeated measures (so- called MMRM) with intervention, 
centre, time (week 1, 2, 4, 8 and 12), and intervention- 
by- time interaction as factors and baseline MADRS score 
as covariate. The error terms are assumed to follow a 
multivariate normal distribution with unstructured cova-
riance. Least squares mean changes from baseline will be 
reported for both groups with 95% CI as well as the differ-
ence between the least squares SIM+ES group means with 
95% CI and p- value testing the null hypothesis of no 
treatment effect. Although the model described above is 
robust to a certain extend to missing data, sensitivity anal-
yses will be performed as supporting analyses including 
multiple imputation and last- observation- carried- forward. 
The latter will mainly be performed to facilitate compar-
ison with previous trials.
The analyses of all secondary endpoints and safety param-
eters will have an exploratory character and will therefore 
not be adjusted for multiple testing. The secondary effi-
cacy endpoints MADRS- response and MADRS- remission, 
and MADRS- MCID within 12 weeks will be analysed by 
logistic regression models with intervention and centre as 
factors and baseline MADRS as covariate. The treatment 
effects will be reported as ORs with 95% CI and p- values 
testing the null hypotheses of no treatment effect. The 
analyses of continuous secondary efficacy endpoint as 
well as SOFAS, and EQ- 5D- 3L will follow the same lines 
as the primary outcome. All details of the statistical anal-
yses including definitions of the analyses populations will 
be specified in the statistical analysis plan, which will be 
finalised before database lock and unblinding. All statis-
tical analyses will be carried out using SAS software or the 
R package.
Patient and public involvement
A patient representative from the German Depression 
League (‘Deutsche Depres- sionsliga’), the umbrella 
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was involved during the development of the study 
protocol. She will also be part of the Data and Safety 
Monitoring Board (DSMB) to represent the patient 
perspective.
ETHICS AND DISSEMINATION
This trial will be conducted in accordance with the 
current guidelines of International Conference on 
Harmonisation- Good Clinical Practice (ICH- GCP). GCP 
is an international ethical and scientific quality standard 
for designing, conducting, recording and reporting trials 
that involve the participation of human subjects. Compli-
ance with this standard provides public assurance that the 
rights, safety and well- being of trial subjects are protected, 
consistent with the principles that have their origin in the 
Declaration of Helsinki, and that the clinical trial data are 
credible. Informed consent will be obtained for screening 
and for participation in the study. Study protocol, patient 
information and consent form have been approved 
by the relevant Ethics Committees and the relevant 
federal authority (Bundesinstitut für Arzneimittel und 
Medizinprodukte—BfArM). The Ethics Committee will 
immediately be informed (by the sponsor/sponsor repre-
sentative) of all changes to the protocol (according to 
GCP- V § 10) and of all events that could affect a patient’s 
safety. The Ethics Committee will also be informed of all 
suspected SUSARs and of regular or premature termina-
tion of the study. We prospectively registered our study in 
the  clinicaltrials. gov database and German Clinical Trials 
Register. The study results will be published irrespective 
of the study outcome in peer- reviewed journals and at 
(inter- )national conferences.
Study management
The sponsor/sponsor representative of the clinical 
study will have overall responsibility for the study. The 
PI together with each investigator of the study site will 
take clinical responsibility for the research team at each 
site. To enhance monitoring of study, we will seek advice 
from a DSMB comprised of methods and clinical experts 
in psychiatry and one patient representative. Thereby, the 
patients’ perspective will be present at all DSMB meet-
ings. Further details about DSMB including its charter are 
available on request.
Authorised representatives of the sponsor, a regulatory 
authority or an Independent Ethics Committee may visit 
the centre to perform audits or inspections, including 
source data verification. The purpose of a sponsor audit 
or inspection is to systematically and independently 
examine all study related activities and documents to 
determine whether these activities were conducted, and 
data were recorded, analysed and accurately reported 
according to the protocol, GCP, ICH guidelines and any 
applicable regulatory requirements.
Perspectives
According to a meta- analysis of small, RCTs, a beneficial 
antidepressive effect of simvastatin is to be expected.14 
Many depressed patients with comorbid obesity might 
additionally benefit from simvastatin in terms of primary 
prevention of cardiovascular disease. The potential bene-
fits of the study by far outweigh the risks associated with 
escitalopram and simvastatin. If successful, our trial would 
have immediate impact on clinical practice because escit-
alopram and simvastatin are available as inexpensive 
generic drugs with established safety.
Ethics approval
The study has been approved by a German ethics 
committee - Ethik- Kommission des Landes Berlin (Refer-
ence: 19/0226 - EK 11) on 22 January 2020.
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countries where data will be collected. Reference to where list of study sites can be 
obtained 
8 
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study 
centres and individuals who will perform the interventions (eg, surgeons, 
psychotherapists) 
9-10; Table S2 
Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and 
when they will be administered 
10-11 
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11b Criteria for discontinuing or modifying allocated interventions for a given trial participant 
(eg, drug dose change in response to harms, participant request, or 
improving/worsening disease) 
16 
11c Strategies to improve adherence to intervention protocols, and any procedures for 
monitoring adherence (eg, drug tablet return, laboratory tests) 
12 
11d Relevant concomitant care and interventions that are permitted or prohibited during the 
trial 
12 
Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable 
(eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, 
time to event), method of aggregation (eg, median, proportion), and time point for each 
outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes 
is strongly recommended 
14; Table 1 & 2 
Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), 
assessments, and visits for participants. A schematic diagram is highly recommended 
(see Figure) 
Table 2; Figure 2 
Sample size 14 Estimated number of participants needed to achieve study objectives and how it was 
determined, including clinical and statistical assumptions supporting any sample size 
calculations 
13-14; Figure 1 
Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size 8 
Methods: Assignment of interventions (for controlled trials)  
Allocation:    
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Sequence generation 16a Method of generating the allocation sequence (eg, computer-generated random 
numbers), and list of any factors for stratification. To reduce predictability of a random 
sequence, details of any planned restriction (eg, blocking) should be provided in a 





16b Mechanism of implementing the allocation sequence (eg, central telephone; 
sequentially numbered, opaque, sealed envelopes), describing any steps to conceal 
the sequence until interventions are assigned 
15 
Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will 
assign participants to interventions 
15-16 
Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care 
providers, outcome assessors, data analysts), and how 
15-16 
 17b If blinded, circumstances under which unblinding is permissible, and procedure for 
revealing a participant’s allocated intervention during the trial 
15-16 
Methods: Data collection, management, and analysis  
Data collection methods 18a Plans for assessment and collection of outcome, baseline, and other trial data, 
including any related processes to promote data quality (eg, duplicate measurements, 
training of assessors) and a description of study instruments (eg, questionnaires, 
laboratory tests) along with their reliability and validity, if known. Reference to where 
data collection forms can be found, if not in the protocol 





 18b Plans to promote participant retention and complete follow-up, including list of any 
outcome data to be collected for participants who discontinue or deviate from 
intervention protocols 
Supplementary 
materials page 3 
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Data management 19 Plans for data entry, coding, security, and storage, including any related processes to 
promote data quality (eg, double data entry; range checks for data values). Reference 






Statistical methods 20a Statistical methods for analysing primary and secondary outcomes. Reference to 
where other details of the statistical analysis plan can be found, if not in the protocol 
17-18; the 
statistical 





 20b Methods for any additional analyses (eg, subgroup and adjusted analyses) 17-18 
 20c Definition of analysis population relating to protocol non-adherence (eg, as randomised 
analysis), and any statistical methods to handle missing data (eg, multiple imputation) 
17-18 
Methods: Monitoring  
Data monitoring 21a Composition of data monitoring committee (DMC); summary of its role and reporting 
structure; statement of whether it is independent from the sponsor and competing 
interests; and reference to where further details about its charter can be found, if not in 
the protocol. Alternatively, an explanation of why a DMC is not needed 
19 
 21b Description of any interim analyses and stopping guidelines, including who will have 
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Harms 22 Plans for collecting, assessing, reporting, and managing solicited and spontaneously 






Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process 
will be independent from investigators and the sponsor 
19 
Ethics and dissemination  
Research ethics approval 24 Plans for seeking research ethics committee/institutional review board (REC/IRB) 
approval 
18 
Protocol amendments 25 Plans for communicating important protocol modifications (eg, changes to eligibility 
criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial 
participants, trial registries, journals, regulators) 
18-19 
Consent or assent 26a Who will obtain informed consent or assent from potential trial participants or 
authorised surrogates, and how (see Item 32) 
10 
 26b Additional consent provisions for collection and use of participant data and biological 
specimens in ancillary studies, if applicable 
- 
Confidentiality 27 How personal information about potential and enrolled participants will be collected, 
shared, and maintained in order to protect confidentiality before, during, and after the 
trial 
17 
Declaration of interests 28 Financial and other competing interests for principal investigators for the overall trial 
and each study site 
26-27 
Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of 
contractual agreements that limit such access for investigators 
17 
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Ancillary and post-trial care 30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who 
suffer harm from trial participation 
- 
Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to participants, 
healthcare professionals, the public, and other relevant groups (eg, via publication, 
reporting in results databases, or other data sharing arrangements), including any 
publication restrictions 
19 
 31b Authorship eligibility guidelines and any intended use of professional writers - 
 31c Plans, if any, for granting public access to the full protocol, participant-level dataset, 
and statistical code 
- 
Appendices    




Biological specimens 33 Plans for collection, laboratory evaluation, and storage of biological specimens for 
genetic or molecular analysis in the current trial and for future use in ancillary studies, if 
applicable 
14 
*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on 
the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative 
Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” license. 
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Supplementary Materials 
1. Safety  
The most prominent risk of Escitalopram is QTc-Prolongation in the ECG that can lead 
to ventricular arrhythmia (torsade des pointes). To exclude patients with QTc-
prolongation an ECG will be conducted at screening. Furthermore, additional safety 
ECG will be conducted at every visit. Importantly, a recent extensive literature review 
on parallel SSRI and statin use concluded the following: “Escitalopram, Citalopram, 
and Paroxetine are almost certain to be safe with all statins”1. 
Simvastatin is offered in an “add-on” design, thus there will be no untreated patients in 
this trial. Invasive interventions beyond ordinary sampling of peripheral venous blood 
will not be performed within this trial, therefore the risks associated with trial 
participation are mainly attributable to Simvastatin that has already been shown in 
depressed patients to be safe and well tolerated in combination with an SSRI2. It has 
been suggested that both for the lipid-lowering effects and for the pleiotropic effects of 
statins a high dose is more effective than a low dose3-5. Especially in studies examining 
effects of statins on diseases of the central nervous system such as multiple sclerosis 
and mild cognitive disorder a high dose of Simvastatin (60 – 80 mg/d) has been 
administered6-8. One of the most important side effects of Simvastatin is dose-
dependent risk of myopathy. The combined incidence for myopathy/rhabdomyolysis 
under Simvastatin was 0.03% for 20 mg/d, 0.08% for 40 mg/d and markedly went up 
to 0.61% for 80 mg/d according to latest version of German Summary of Product 
Characteristics. To minimize the risk of Simvastatin and examine the pleiotropic effects 
of Simvastatin in depression, we will use it in a medium dose (40 mg/d) and not a high 
dose (80 mg/d). In addition to assessing safety laboratory values including creatine 
kinase (CK) at screening, baseline, at week 4, week 8 and week 12, it will be explicitly 
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asked during each visit if the patient experienced unexplained muscle pain or dark 
urine as a sign of rhabdomyolysis. Furthermore, we will not include particularly 
vulnerable patients (e.g. patients with renal impairment, untreated hypothyroidism or 
history of muscle toxicity under statins or fibrates) to our study.  
For women of childbearing potential, a highly sensitive serum human chorionic 
gonadotropin (hCG) test will be conducted at screening visit, baseline, week 4, week 
8 and at the end-of-study. Highly effective contraception in women (defined as pearl 
index < 1), or complete abstinence of intercourse (during study participation) is 
required for study participation (see exclusion criteria in table S2).  
2. Definitions of AE, SAE, and SUSAR 
Adverse event (AE): An AE is an untoward medical occurrence in a patient or clinical 
trial subject administered a medicinal product and which does not necessarily have a 
causal relationship with this treatment. An AE could be diseases, signs or symptoms 
which occur or worsen after enrolment of the patient in the clinical trial. All AEs reported 
by the subject or observed by the Investigators will be recorded at each visit and 
evaluated to determine whether it constitutes a serious adverse event. 
Serious Adverse Event (SAE): A SAE is an untoward medical occurrence or effect that 
at any dose results in death, is life-threatening, requires hospitalization or prolongation 
of existing hospitalization, results in persistent or significant disability or incapacity, is 
a congenital anomaly or birth defect, or requires a higher benzodiazepine regimen or 
prescription of antipsychotics (“rescue medication”). 
Suspected Unexpected Serious Adverse Reactions (SUSAR): A SUSAR is any 
suspected adverse reaction related to the study treatment that is both serious and 
unexpected.  
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3.1 Premature termination of the individual patient 
Patients are free to withdraw from participation in the study without specifying any 
reasons. An Investigator may discontinue or withdraw a participant from the study if 
any clinical adverse event, laboratory abnormality, or other medical condition occurs 
such that continued participation in the study would not be in the best interest of the 
participant. In particular the following AE, laboratory abnormality, or other medical 
condition will lead to immediate discontinuation of the individual participant: report of 
any unexplained muscle pain, tenderness or weakness if accompanied by malaise or 
fever, hyperbilirubinemia or jaundice, interstitial lung disease, QTc prolongation ≥ 500 
ms or ≥ 60 ms increase from baseline, seizures, activation of mania/hypomania, 
abnormal bleeding event (e.g. ecchymoses, purpura), serotonin syndrome, angle 
closure glaucoma, clinically significant worsening of depression severity 
operationalized as a change score of 6 or 7 (“much worse” or “very much worse”) in 
the Clinicians’ Global Impression of Improvement scale (CGI-I) in two successive visits, 
clinically significant laboratory abnormalities, acute suicidal ideation (MADRS item 10 
> 4), and pregnancy. In the case of premature termination, the reason for withdrawal 
will be documented and the patient will be followed for safety and efficacy until the end 
of the study (week 12). 
3.2 Premature termination of the clinical study 
According to the German Summary of Product Characteristics for Simvastatin, the 
combined incidence for myopathy/rhabdomyolysis in 41.413 patients treated for at 
least 4 years was 0.08% for 40mg/d Simvastatin. Severe symptomatic hyponatremia 
(serum sodium [SNa] <125 mmol/L) is a rare but potentially fatal complication of 
Escitalopram. Signs and symptoms of hyponatremia include headache, difficulty 
concentrating, memory impairment, confusion, weakness, and unsteadiness and can 
be as severe as hallucination, syncope, seizure, coma, respiratory arrest, and death. 
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Therefore, the whole study may be discontinued at the occurrence of 
“myopathy/rhabdomyolysis” as defined by the German Summary of Product 
Characteristics for Simvastatin [muscle pain, tenderness or weakness with creatine 
kinase (CK) above ten times the upper limit of normal (ULN)] in more than 5 
participants or “severe symptomatic hyponatremia” (serum sodium [SNa] <125 mmol/L) 
in more than 5 participants. In addition, an early discontinuation of the trial may be 
decided if new scientific data during the course of the trial changes the risk-benefit-
balance significantly. If such data emerges, recruitment and treatment of currently 
treated patients will be paused immediately. A final decision on continuation or 
termination of the trial will then made by the Sponsor based on the recommendation 
of the Data and Safety Monitoring Board (DSMB). 
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Table S2: SIMCODE study inclusion and exclusion criteria 
Inclusion criteria 
- Written informed consent is present  
- The patient has the capacity to give consent (He/she is able to understand the nature and anticipated effects/side effects of the proposed medical 
intervention)  
- The patient has a major depressive episode according to DSM 5 (Diagnostic and Statistical Manual of Mental Disorders 5th Edition) 
- The patient has a score of ≥ 18 in the Montgomery-Asberg Depression Rating Scale (MADRS)  
- The patient has a body mass index ≥ 30  
- The patient’s age is between 18 and 65 years (≥ 18 und ≤ 65) 
- The patient has not given childbirth within the 6 months prior to study entry and is not breastfeeding 
- In case of non-psychotropic medication: The patient received stable pharmacological medication for at least 14 days prior to study entry (any changes in 
medication dose or frequency of therapy must be answered with no) 
- The patient did not take antidepressants during the last 7 days prior to study entry (discontinuation of effective medication to enable study participation is 
prohibited) 
- The patient did not receive prior treatment with Escitalopram in index episode 
- The patient had less than three (<3) trials with antidepressants in index episode  
- The patient does not have a history of non-response to Escitalopram 
- The patient did not receive treatment with ketamine, electroconvulsive therapy (ECT) or other stimulatory treatments in index episode 
- The patient does not meet any of the following criteria: schizophrenia, schizoaffective disorder, bipolar disorder 
- The patient is not diagnosed with dementia and does not have moderate or severe impairment of general cognitive function according to clinical impression  
- The patient does not have clinically relevant elevated liver enzymes [GOT or GPT > 3 x upper limit normal (ULN)] and does not have elevated Carbohydrate 
Deficient Transferrin (CDT) ≥ 2.4 % 
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Continued Table S2: SIMCODE study inclusion and exclusion criteria 
Inclusion criteria 
- The patient does not meet the criteria for alcohol use disorder (DSM-5: 303.90; ICD-10: F10.20) or substance use disorder (DSM-5: 304; ICD-10: F11.20 
– F19.20) in M.I.N.I. for DSM-5 and a urine/serum drug screening is negative (except for benzodiazepines and opiates) 
- The patient does not have a history of suicide attempt 
- The patient does not have diagnosed epilepsy or increased bleeding diathesis or a history of angle closure glaucoma or other glaucoma 
- The patient did not have bariatric surgery prior to study entry  
- The patient does not have a known allergy or contraindication against Escitalopram or Simvastatin 
- The patient does not meet any of the following criteria: hereditary muscle disease, known history of rhabdomyolysis, elevated creatine kinase (CK) outside 
of the sex-specific reference intervals, history of muscular symptoms under treatment with statins or fibrates 
- The patient does not have elevated TSH level outside of the age- and sex-specific reference intervals. 
- The patient does not have insulin-dependent diabetes mellitus 
- The patient does not have uncontrolled hepatic disorder, renal or cardiovascular disease 
- The patient does not have untreated hypothyroidism 
- The patient does not have a history of myocardial infarction or stroke  
- The patient does not have symptomatic peripheral arterial disease  
- The patient does not have monogenic familial hypercholesterolemia  
- The patient does not have clinically significant laboratory abnormalities  
- The patient did not participate in other interventional trials during the 6 months before and at the time of this trial  
- The patient is not an employee of the Investigator study site, or a family member of the employees or the Investigator, or otherwise dependent on the 
Sponsor, the Investigator or the Investigator study site 
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Continued Table S2: SIMCODE study inclusion and exclusion criteria 
Exclusion criteria 
- The patient has current use of statins (for visits 2-6 applies: except for IMP Simvastatin) 
- The patient has current use of antidepressants (for visits 2-6 applies: except for standard medication Escitalopram)  
- The patient has acute suicidal tendencies (MADRS Item 10 > 4) 
- The patient uses potent CYP3A4-inhibitors (e.g. clarithromycin, erythromycin, HIV protease inhibitors)  
- The patient uses potent CYP3A4 inductors (Carbamazepine, Efavirenz, Nevirapine, Etravirine). 
- The patient uses Fibrates, Amiodarone, Amlodipine, Verapamil, Fluconazol, Diltiazem, Fusidic acid, Niacin or Lomitapide or BCRP-Inhibtors (e.g. Elbasvir 
or Grazoprevir) 
- The patient uses Gemfibrozil, Ciclosporin or Danazol 
- The patient has known hypersensitivity to other ingredients of Simvastatin and Escitalopram [butylated hydroxyanisole, microcrystalline celluose, citric 
acid, starch, lactose, magnesium stearate, hypromellose, talc, titanium dioxide, iron oxies, colloidal silicon dioxide, croscarmellose sodium, polyethylene 
glycol] 
- The patient uses medication that is associated with QTc-prolongation [antiarrhythmica class IA and III, antipsychotics (e.g. Haloperidol), phenothiazines, 
tricyclic antidepressants, antibiotics (e.g. Moxifloxacin), and certain antihistaminergic drugs (e.g. Astemizol, Mizolastine)] 
- The patient has clinically significant abnormalities in 12-lead ECG (e.g. QTc-prolongation ≥ 500 ms or increase ≥ 60 ms from baseline visit) 
- The patient is pregnant  
- The patient with childbearing potential is not willing to use an acceptable form of contraception (defined as Pearl index < 1) 
- The patient has current use of psychotropic medication (e.g. antipsychotics, anticonvulsants, lithium or St. John's Wort) except for benzodiazepines, 
non-benzodiazepines and opiates  
- The patient uses nonselective, irreversible monoamine oxidase (MAO) inhibitor (e.g. Tranylcypromine) or selective, reversible inhibitor of monoamine 
oxidase A (e.g. Moclobemide) or the nonselective, reversible monoamine oxidase inhibitor Linezolid 
- The patient is unwilling to consent to saving, processing and propagation of pseudonymized medical data for study reasons 
- The patient is legally detained in an official institution 
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